Literature DB >> 183052

An ultrastructural study of central nervous system disease produced by wild-type and temperature-sensitive mutants of vesicular stomatitis virus.

M C Dal Canto, S G Rabinowitz, T C Johnson.   

Abstract

Outbred Swiss mice 3 to 4 weeks of age were injected intracerebrally with wild-type vesicular stomatitis virus or its temperature-sensitive (ts) mutants ts 11, ts 22, ts 31, and ts 41. Brain and spinal cord were then studied for pathologic changes by electron microscopy. All mice infected with wild-type vesicular stomatitis virus died within 2 days of inoculation. Diffuse ependymal alterations often culminating in necrosis in brain and especially spinal cord and rare foci of necrosis and mononuclear cell infiltration in the injected hemisphere were the main pathologic changes in these animals. In contrast, mice infected intracerebrally with ts 22 and ts 31 showed their first clinical signs, consisting of hind limb paralysis, on day 4 and did not die until day 7 or 8 after inoculation. Ependymal alterations were of less severe degree in these animals, whereas the most striking changes were those of status spongiosus limited to the gray matter of the spinal cord. Such status spongiosus was mainly due to ballooning of dendrites and astrocytic processes, although myelin and neurons were also occasionally involved. Mice infected with ts 11 and ts 41, on the other hand, remained clinically well and failed to show significant pathologic features at 4 and 8 days after intracerebral inoculation. This study would indicate that some ts mutants of vesicular stomatitis virus are capable of altering the fulminating disease produced by the parent virus and of producing strikingly different pathologic changes.

Entities:  

Mesh:

Year:  1976        PMID: 183052

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

Review 1.  Papovaviral persistent infections.

Authors:  L C Norkin
Journal:  Microbiol Rev       Date:  1982-12

2.  Role of VSV G antigen in the development of experimental spongiform encephalopathy in mice.

Authors:  O Robain; F Chany-Fournier; I Cerutti; M Màzlo; C Chany
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

3.  Ultrastructural-immunohistochemical evidence for a maturation defect of temperature-sensitive G31 vesicular stomatitis virus in murine spinal cord neurons.

Authors:  M C Dal Canto; S G Rabinowitz; T C Johnson; J V Hughes
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

4.  Neuroblastoma cell fusion by a temperature-sensitive mutant of vesicular stomatitis virus.

Authors:  J V Hughes; B J Dille; R L Thimmig; T C Johnson; S G Rabinowitz; M C Dal Canto
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

5.  Murine central nervous system infection by a viral temperature-sensitive mutant: a subacute disease leading to demyelination.

Authors:  M C Dal Canto; S G Rabinowitz
Journal:  Am J Pathol       Date:  1981-03       Impact factor: 4.307

6.  Neurovirulence mutant of vesicular stomatitis virus with an altered target cell tropism in vivo.

Authors:  O T Preble; L E Costello; D D Huang; M A Barmada
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

7.  Detection of vesicular stomatitis virus (VSV) RNA in the central nervous system of infected mice by in situ hybridization.

Authors:  J G Fournier; O Robain; I Cerutti; I Tardivel; F Chany-Fournier; C Chany
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Neuropeptide-induced hypothermia and the course of central nervous system disease mediated by temperature-sensitive mutants of vesicular stomatitis virus.

Authors:  S C Doll; T C Johnson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Comparative neurovirulence of selected vesicular stomatitis virus temperature-sensitive mutants of complementation groups II and III.

Authors:  S G Rabinowitz; J Huprikar; M C Dal Canto
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.